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Summary
In 2003, the Fund for the Replacement of Animals in Medical Experiments (FRAME) revealed that the potency of botulinum toxin for
use as a popular wrinkle treatment is assessed by using the LD50 Test. The endpoint in this mouse-based testing is death through
suffocation. In 2004, The Humane Society of the United States (HSUS) sought to work with Allergan, the US-based manufacturer of
Botox® Cosmetic, and the U.S. Food and Drug Administration (FDA), on ways to refine, reduce, and replace this LD50 testing. This
article summarises The HSUS’s campaign in the United States and provides an update on FRAME’s continuing efforts in Europe.
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Introduction

Botulinum toxin, produced by various bacteria, including
Clostridium botulinum, is one of the most powerful biological
toxins known, which blocks transmission of nerve impulses to
muscles. Eight subspecies of the bacterium produce seven distinct types of toxin (types A-G), which act through different
mechanisms. Food-borne botulinum toxin causes Botulism.
Several companies use botulinum toxin as the active ingredient in therapeutic products for treatment of conditions such as
cervical dystonia, strabismus, blepharospasm, and hyperhidrosis. For example, Ipsen Limited UK markets a botulinum toxin
Type A product, Dysport®, while the Allergan Corporation,
based in the United States, markets two botulinum toxin Type A
products: Botox®, for therapeutic applications, and Botox®
Cosmetic, the popular wrinkle treatment – a cosmetic application.
Botulinum toxin is produced for commercial application in
fermentation batches seeded with the bacteria. The standard
method for assessing the potency of botulinum toxin batches is
a mouse LD50 Test (Bottrill, 2003). In this procedure, mice are
sorted into dose groups, given a single injection of toxin, and
monitored over 3-4 days. Death is the endpoint, which results
from suffocation through paralysis of the diaphragm musculature. Although the precise details are not available, over 100
mice are used per test, and the mouse testing is carried out up to
three times prior to batch release. Calculations from the test data
yield an LD50 value (the dose which would kill half the number
of animals in a test group), which is then standardised as one
“mouse unit”.
The LD50 testing of botulinum toxin products runs counter to
three trends in the application of the Three Rs of replacement,
reduction, and refinement, and in animal welfare generally. First,
the use of the LD50 test is being phased out worldwide. This was
symbolised most dramatically in the field of industrial chemicals, when, in 2002, the Organization for Economic Cooperation
and Development deleted the LD50 Test (its Test Guideline 401)
from its Health Effects Test Guidelines (OECD, 2002). Second,
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the use of death as an endpoint is the bête noire of the growing
field of humane endpoints (Olfert et al., 1998; OECD, 2000;
ILAR, 2000). The third trend, applicable to LD50 testing of
Botox Cosmetic, is the phasing out of animal testing of products
with a cosmetic use. For example, in 2004, the European Union
banned all forms of animal testing of cosmetic products
(Europa, 2003).
In 2003, the Fund for the Replacement of Animals in Medical
Experiments (FRAME) drew attention to the issue of LD50 testing of botulinum toxin products with the publication of an
exposé entitled “Growing Old Disgracefully ...” (Bottrill, 2003;
Balls, 2003). The Humane Society of the United States (HSUS)
then took up the challenge in the USA. FRAME focuses its
efforts on the European scene, and The HSUS on the US scene,
but we are pleased to have this opportunity to show that we work
together, and to provide brief updates on earlier assessments of
alternatives to the mouse LD50 testing of botulinum products
(Bottrill, 2003; Balls, 2003) and on the FRAME campaign, as
well as a summary of the HSUS campaign.

Background
An update on alternatives for the potency
assessment of botulinum toxin products

Table 1 summarises some of the potential alternatives to the
mouse LD50 Test for assessing the potency of botulinum toxin
products. Much of this information is taken from Bottrill’s 2003
review. Potential refinements include mouse-based methods that
assess local paralysis either in vivo or ex vivo, in contrast to systemic paralysis in vivo, as in the LD50 assay. Potential replacements target the specific molecules involved in nerve
transmission that are disrupted by the various types of
botulinum. For example, the SNAP-25/endopeptidase assay
(Ekong et al., 1997) assesses in vitro the extent to which
botulinum toxin Type A disrupts the activity of synaptosomalassociated protein of molecular mass 25kDa (SNAP-25), a
molecule with a critical role in transmitting nerve signals.

153

THEME 3, SESSION 3.4

In their recent monograph on testing botulinum toxin, the
influential European Pharmacopeia (Anon., 2005) recognised
the potential of these methods to substitute for the mouse LD50
test, stating that: “After validation with respect to the LD50 assay
(reference method), the product may also be assayed by other
methods that are preferable in terms of animal welfare”, including the in vitro endopeptidase assay, the ex vivo assay using the
mouse phrenic nerve diaphragm, and the “mouse bioassay using
paralysis as the endpoint.”
The European Pharmacopeia monograph was published prior
to the publication of the Endopep-MS assay in vitro method
(tab. 1), which has the potential advantage of permitting assessments of the potencies of all of the types of botulinum toxin.
An update on the FRAME campaign

FRAME is concerned that Ipsen Limited UK continues to use
the mouse LD50 test to measure the potency of Dysport, and
urges the Home Office (the British Government department
responsible for the control of animal experimentation) to do
more to bring about an end to the animal testing of botulinum
toxin products for clinical and/or cosmetic use, and considers
that the Government should close the loophole which permits
botulinum toxin destined to be used for cosmetic purposes to be
tested in animals, despite the ban on testing cosmetic products in
the UK. The claim is that botulinum toxin is only officially
licensed (and therefore tested) for clinical use, and its use for
cosmetic purposes involves a private contract between a physician and a patient, at their own risk.
FRAME applauds the efforts of the UK national control
agency, the National Institute for Biological Standards and
Control (NIBSC), to develop and use refinement and replacement alternatives. The NIBSC uses in vitro methods on a routine
basis, and only uses a non-lethal in vivo test when, rarely, the
results of an in vitro test are inconclusive or close to pass/fail
specifications.
FRAME is also encouraged by the effort being put by the
NIBSC into the development of methods which could totally
obviate the need for animal testing (eg, Ekong et al., 1997), and
also that Ipsen Limited UK are working with the NIBSC and
others to develop suitable batch release tests.
Meanwhile, at the European level, the European Centre for the
Validation of Alternative Methods (ECVAM) and the European
Directorate for the Quality of Medicines (EDQM) are working
together and with others to review what progress is being made
in applying the Three Rs to botulinum toxin testing and to assist
in moving forward.

Summary of HSUS campaign

The HSUS campaign focuses exclusively on the testing of Botox
Cosmetic by its manufacturer, Allergan, Inc., based in
California. Botox Cosmetic wrinkle treatment is the most common cosmetic procedure in United States, with 2.8 million treatments carried out in 2004 (Allergan, 2005; ASAPS, 2005),
accounting for 40% of net Botox sales or $295M. The HSUS
regards the LD50 testing of products for cosmetic use as unacceptable, and seeks to hold Allergan accountable.
The strategy was to first seek to work with Allergan, and only
if that approach failed, would The HSUS seek to pressure the
company from the outside. Three things were sought from
Allergan:
1. public disclosure of the details of its current potency testing
of Botox Cosmetic;
2. public disclosure of the details of its current efforts to develop
alternatives to the mouse LD50 testing of Botox Cosmetic; and
3. adoption of a well-funded and publicly available plan to
rapidly end the LD50 testing of Botox Cosmetic.
For several months, beginning in January 2004, The HSUS
engaged in cordial, but largely fruitless, communication with
Allergan. The company communicated with The HSUS only
through its legal staff. At The HSUS’s request, the company met
with Alan Goldberg, Director of the Johns Hopkins Center for
Alternatives to Animal Testing (CAAT), to discuss potential
CAAT/Allergan collaboration on alternatives, but the company
never followed up this suggestion.
Allergan did confirm that the company uses the LD50 Test to
assess the potency of Botox Cosmetic, and claimed to have an
active alternatives program to replace this testing. However,
the company provided few details either of its current testing
practices or of its alternatives efforts. In its defense, Allergan
noted that Botox Cosmetic and its sister product, Botox, share
the same active ingredient, botulinum toxin Type A, so LD50
testing for the two products is inextricably linked and testing
for cosmetic purposes cannot be cleanly separated from testing for therapeutic purposes. Allergan also noted the international regulations calling for the LD50 testing of botulinum
toxin products.
The HSUS took note of these claims, but concluded that they
collectively failed to justify the company’s secrecy concerning
its testing and alternatives practices. In The HSUS’s view, any
company that is making $300M a year on the backs of suffocating animals deserves to be held publicly accountable for working towards an urgent solution, especially in the context of a
cosmetic application.

Tab. 1: Promising alternative methods to the mouse LD50 test for assessing the potency of botulinum toxin products
Name of Test
Mouse hind-limb assay
Abdominal ptosis assay
Mouse phrenic nerve-hemidiaphragm system
SNAP- 25/Endopeptidase assay
Endopep-MS
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System
in vivo
in vivo
ex vivo
in vitro
in vitro

Endpoint
local paralysis
local paralysis
muscle contraction
molecular disruption of nerve transmission
molecular disruption of nerve transmission

Duration
2 days
< 1 day
< 1 day
< 1 day
< 1 day

Reference
Pearce et al., 1995
Takahashi et al., 1990
Bigalke et al., 2001
Ekong et al., 1997
Boyer et al., 2005
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Consequently, The HSUS decided to implement the second,
conditional part of its strategy towards Allergan, namely, applying public pressure to the company. Beginning in October 2004,
The HSUS began issuing calls to its members and constituents
to urge the company to work with The HSUS on rapidly
replacing LD50 testing for Botox Cosmetic. The calls were
issued through the organisation’s electronic and hard-copy publications. In response to one appeal, thousands of e-mails to
Allergan compelled the company to shut down an e-mail
account.
Since Allergan refused to work with The HSUS or to disclose
information about its testing and alternatives practices, The
HSUS turned to the U.S. Food and Drug Administration (FDA),
which had approved Botox Cosmetic and Botox. The FDA regulates these products as pharmaceuticals, and now oversees their
manufacture and sale. The HSUS was specifically interested in
information about the potency testing currently required or
encouraged for these products. It was hoped that the agency
could help answer several key questions, including the following.
1. What are the current testing practices?
2. Does the FDA require or encourage these practices?
3. How have these practices changed over the years?
4. What is the FDA itself doing to promote LD50 alternatives?
In 2004, The HSUS filed two Freedom of Information Act
requests with the FDA, in order to obtain the sought-after information, but the agency was largely unresponsive. Consequently,
the HSUS initiated legal action in 2005 to obtain the requested
documents. This legal action is still pending.

Discussion and conclusions

FRAME, The HSUS, and similar organisations engage in advocacy of the Three Rs, because they want to accelerate the pace
of progress in the development, validation, and implementation
of methods to replace, reduce and refine animal experimentation
and testing. In the case of the potency testing of botulinum toxin
products, it is clear that some progress on alternative methods
had been made prior to the launch of the FRAME and HSUS
campaigns. However, it is clear that an unknown, but undoubtedly large number of mice were being used, and are still being
used, in painful and lethal procedures for the testing of products
destined for use for cosmetic, as well as for clinical, purposes.
We are prepared to give Allergan, Ipsen Limited UK, and other
manufacturers of botulinum toxin products the benefit of the
doubt, by accepting that they are seeking to contribute to
progress in the right direction.
Given this concession, some might conclude that our advocacy efforts are misplaced. We would disagree. As outlined
above, the LD50 testing of botulinum toxin products in general,
and of products for cosmetic use in particular, runs counter to
three trends: the phasing out of the LD50 test, of the use of death
as an endpoint, and of any animal testing of products with a cosmetic purpose. Consequently, the continuation of such testing is
particularly out of step with the times, and is therefore particularly in need of scrutiny and action. Instead of assurances that
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progress is being made, what is needed is a demonstration of
goodwill and verifiable action on the part of the manufacturers
and the agencies responsible for the registration and use of pharmaceutical and cosmetics products and for the regulation of laboratory animal experimentation. The technical challenges to
developing a non-animal alternative for botulinum toxin product
testing are formidable, and are best met with collaborative
efforts open to scrutiny and to constructive criticism, not with
alleged programs happening behind closed doors. We note for
the record that none of the published studies of alternatives to
LD50 testing of botulinum toxin products, of which we are
aware, were conducted by scientists working for the manufacturers of these products.
One of the factors that has worked against the FRAME and
HSUS campaigns is the limited media interest that these efforts
have generated. We suspect that this stems, in part, from limited
public (and media) sympathy for mice. This is unfortunate,
given that the capacity of mice to suffer is similar to that in most
other animals used in laboratories. We suspect that the complexity of the relevant issues also limits the media appeal of our campaigns, including the technical nature of the non-animal
alternatives and the dual use of botulinum toxin production
batches for both therapeutic and cosmetic purposes. Our campaigns are also hampered by the lack of publicly available
details about current testing practices and alternatives efforts.
FRAME is encouraged by the attention now being paid by the
Home Office to the questions we have raised, and by the work
being conducted by the NIBSC, as well as by the attention now
being paid to the botulinum toxin testing issue by ECVAM and
the EDQM. However, having legitimately raised an important
issue of great concern in relation to both the severity of animal
procedures and the need for an active commitment to finding relevant and reliable replacement alternatives, FRAME will expect
progress to be made and to be kept fully informed about it.
The HSUS anticipates that its legal action against the FDA
will yield critical information about the botulinum toxin testing,
including the numbers of animals used per test and the number
of tests conducted prior to release of a given batch of product. If
Allergan continues to spurn legitimate demands for information
and for co-operation, The HSUS will seek to increase the public
pressure on the company, in a manner consistent with the successful campaign strategy of that late American activist, Henry
Spira (Singer, 1998).
Meanwhile, both FRAME and The HSUS are willing to work
collaboratively with the relevant authorities, and with institutions such as ECVAM, the EDQM, the Interagency
Coordinating Committed on the Validation of Alternative
Methods (ICCVAM), and the NIBSC, to accelerate the pace of
progress, in the confident belief that we all share the same interest in making available products which are made as safe as possible for human use, but by using modern methods and
progressively reducing reliance on the traditional application of
painful test procedures to laboratory animals.
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